A Pilot Study of Neo-Adjuvant Everolimus in Patients With Advanced Renal Cell Carcinoma Undergoing Definitive Therapy With Radical Nephrectomy, or Cytoreductive Nephrectomy - Analysis of Serum and Tissue Biomarkers.

Trial Profile

A Pilot Study of Neo-Adjuvant Everolimus in Patients With Advanced Renal Cell Carcinoma Undergoing Definitive Therapy With Radical Nephrectomy, or Cytoreductive Nephrectomy - Analysis of Serum and Tissue Biomarkers.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Biomarker; Therapeutic Use
  • Acronyms MIURCCEVERO
  • Most Recent Events

    • 12 Oct 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017.
    • 12 Oct 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016.
    • 17 Mar 2015 Planned End Date changed from 1 Jan 2015 to 1 Jan 2016 as per Clinicaltrial.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top